Research on human embryonic stem cells – a shaky future marked by murky decisions


A Rome – Human stem cell research has become something of a studia non grata in Italian politics. Research into human embryonic stem cells was explicitly excluded from a recent call for proposals to fund stem-cell biology. Three scientists subsequently appealed against the exclusion, but lost the first round in court. This could mark the starting point of a lengthy legal battle to define the future of embryonic stem cell research in Italy. Just three days before the deadline for submitting grant proposals on July 20th, an administrative court in Rome backed up the government position and rejected the scientists’ appeal.
Political support for stem cell research in Italy has a turbulent history. In 2007, then health minister Livia Turco cancelled a a3m fund after complaints about the nontransparent distribution of the monies. After some squabbling, Turoc agreed to set up a new a8m fund, and to guarantee proper reviewing procedures. In spring of last year, after the ruling centre-left government lost to the coalition headed by Silvio Berlusconi, Turco’s successor Ferrucio Fazio promised to continue the fund.
A committee of five experts was then established to formulate a call for projects. Giulio Cossu, a developmental biologist at the San Raffaele scientific institute in Milan and one of the committee members, says that the group formulated a text that included every type of stem-cell proposal.

The mystery of who wrote what

But when the proposal was published, a sentence had been added explicitly excluding projects involving human embryonic stem cells. The proposal appeared online after a February meeting of Italy’s State-Regions Conference. Made up of representatives from the 20 Italian regions, that body decides how national health funds are distributed. In media interviews, Fazio dismissed rumours in spring that the sentence had been added by someone within his ministry. He insisted that the sentence had been added by the regions.
Elena Cattaneo from the University of Milan, along with Elisabetta Cerbai from the University of Florence and Silvia Garagna from the University of Pavia, filed a lawsuit that was rejected by a court in Rome on formal grounds. The judges noted that only institutional recipients of the funding – like regional councils and universities – are allowed to appeal against the government. Individual researchers, they said, don’t have that option.
The Italian law that regulates in vitro fertilisation (Legge 40) forbids the creation of new cell lines from embryos for scientific purposes, but does not prevent researchers from studying them. Cattaneo’s lawyer, Vittorio Angiolini, told the magazine Science that the next move will be to appeal to a higher Italian court, the State Council. He said he believes that the judges’ decision is by no means justified from a legal perspective.



Rome/Milan – Together with two Italian research institutes, British drug giant Glaxo­SmithKline has begun to develop a therapy for the heriditary immune defect ADA-SCID, which affects only 350 children worldwide. Fondazione...



Rome – When it comes to GMOs, the gap between Italy’s federal government and its regions that has marked the country for years is rapidly widening into a gulf. The latest rupture was on display at the October session of the...



Valletta – A new Life Sciences Park is to be created on the outskirts of Malta’s capital Valletta. The EUR20m project will provide space for companies operating in biotechnology and medical sciences. The park will be located in...



Verona – Scientists at Glaxo­SmithKline in Verona have discovered that specific neurons in the amygdala control how mice react to fear stimuli. When they switched off the so-called Type I cells in the animals’ amyg­dala, the mice...



San Michele all’Adige – The genetic code of the Golden Delicious apple has been deciphered. Led by Riccardo Velasco at the Edmund Mach Foundation in San Michele all’Adige in Italy’s Trentino province, a team of scientists from 20...



: It’s hard to be a pro-GMO campaigner in Italy. Since 2001, the regions there have not implemented the plans for coexistence that were suggested by a ministerial decree. Instead, there was a de facto Italian moratorium on GM...



Milan – One of Italy’s biggest biotech players wants to raise EUR58m to boost its pipeline of cancer therapies. The round will be closed on July 16th. With operating costs of EUR22.5m and a total loss of about EUR17m in 2009,...



Milan – Italian researchers have restored sight to blind patients using stem cells from the patients’ own bodies. In a study published by the New England Journal of Medicine (10.1056/NEJMoa0905955), scientists from Modena and...

Displaying results 21 to 30 out of 181

< Previous 21-30 Next >

© 2007-2016 BIOCOM


Current issue

All issues

Product of the week


Stock list

All quotes


  • PLETHORA (UK)3.38 GBP12.67%
  • NORDIC NANOVECTOR (N)27.10 NOK10.61%


  • THERAMETRICS (CH)0.02 CHF-33.33%
  • 4SC (D)2.38 EUR-8.11%
  • RENEURON (UK)3.38 GBP-3.43%


  • GALAPAGOS (B)51.60 EUR30.0%
  • NICOX (F)10.95 EUR28.1%
  • GENMAB (DK)1194.00 DKK24.0%


  • THERAMETRICS (CH)0.02 CHF-33.3%
  • 4SC (D)2.38 EUR-27.9%
  • MOBERG PHARMA (S)38.70 SEK-20.4%


  • KARO BIO (S)30.30 SEK1961.2%
  • CHRONTECH PHARMA (S)0.34 SEK1600.0%
  • NICOX (F)10.95 EUR488.7%


  • BB BIOTECH (D)44.70 EUR-84.3%
  • BIOTEST (D)17.05 EUR-78.3%

No liability assumed, Date: 30.05.2016


All Events


Basel (CH)

Chemspec Europe 2016